# U.S. Food and Drug Administration

Type: organization (FDA)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/us-food-and-drug-administration-organization
Canonical HTML page: https://gethealthbrief.com/entity/us-food-and-drug-administration-organization

## Timeline

- **2027-01-01**: Potential EU Launch — Target window for commercial availability of iopofosine I 131 in Europe.
- **2026-09-30**: EMA Submission — Planned filing of Conditional Marketing Authorization for iopofosine I 131.
- **2026-06-30**: CLR 125 Data — Expected early data readout from Phase 1b study in triple-negative breast cancer.
- **2026-04-14**: JPM Q1 Earnings Report — JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
- **2026-04-10**: FDA Orforglipron Decision — Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-03-05**: Earnings Release — Both companies report Q4 and FY 2025 financial results and business highlights.
- **2026-03-04**: Financial Results — Company reports 2025 results and provides corporate update.
- **2026-03-04**: FDA Partial Hold — FDA notifies PepGen of partial clinical hold on Freedom2 trial.
- **2026-01-15**: Regulatory Designations — FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
- **2025-12-31**: Fiscal Year End — Cellectar completes a year of pipeline advancement and platform validation.
- **2025-12-31**: Fiscal Year End — OmniAb and PepGen conclude their 2025 fiscal years.
- **2025-Q4**: Phase II Data Publication — Results showing efficacy without hormonal side effects published in The Lancet.

## Recent coverage (5 stories)

### FDA’s First MRTP for Nicotine Pouches: 10 ZYN Flavors Cleared with Reduced‑Exposure Claim
2026-07-04 09:15:21 · Sentiment: Positive · Impact: 7/10 · Sources: 2

The FDA authorized modified risk orders for ten ZYN nicotine pouch flavors, permitting claims that they reduce exposure to harmful chemicals. Health policymakers face new questions on harm reduction, youth appeal, and postmarket proof.
Full story: https://gethealthbrief.com/story/mrtp-zyn-10-flavors-public-health

### Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug
2026-03-25 12:12:33 · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Full story: https://gethealthbrief.com/story/hope-medicine-hmi115-phase-3-endometriosis

### April Catalysts: Eli Lilly’s Oral GLP-1 Decision and JPM Earnings Outlook
2026-03-23 00:14:25 · Sentiment: Positive · Impact: 7/10 · Sources: 5

Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Full story: https://gethealthbrief.com/story/eli-lilly-jpmorgan-april-catalysts-analysis

### OmniAb and PepGen 2025 Results Clouded by FDA Hold on Freedom2 Trial
2026-03-05 05:48:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.
Full story: https://gethealthbrief.com/story/omniab-pepgen-2025-earnings-fda-hold

### Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131
2026-03-05 01:14:36 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
Full story: https://gethealthbrief.com/story/cellectar-biosciences-2025-results-iopofosine-update

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.